AI
TRDA icon

Atom Investors’s Entrada Therapeutics TRDA Stock Holding History

Atom Investors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,812
Closed -$179K – 806
2025
Q3 		$179K Buy
+30,812
New +$180K 0.01% 519

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atom Investors's TRDA Position: Q4 2025 in Review

Atom Investors sold out of Entrada Therapeutics (TRDA) in Q4 2025, closing a stake of 30,812 shares — an estimated $179K sold.

Atom Investors first reported a position in TRDA in Q3 2025 and held it in 1 quarter. The position peaked at $179K in Q3 2025. 114 funds tracked by Wall St. Rank hold TRDA as of Q4 2025.

  • Atom Investors reported no remaining Entrada Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 30,812 Entrada Therapeutics shares in Q4 2025, an estimated $179K.
  • Atom Investors first reported a position in Entrada Therapeutics in Q3 2025 and held it in 1 quarter.
  • Atom Investors's Entrada Therapeutics position peaked at $179K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.